Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › testicular germ cell tumor

Testicular germ cell tumor

Part of Cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for testicular germ cell tumor

7 trials tracked for testicular germ cell tumor: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 200 citations.

7Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 5 Other / NA 1
  1. Phase 3 Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors Completed · 200 cited
  2. Phase 2 Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin Completed
  3. Phase 2 Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors Completed
  4. Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors Completed
  5. Phase 2 Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment Completed
  6. Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer Completed
Show 1 more trials
  1. N/A Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Testicular germ cell tumor: what the trials found

Clinical investigations into the management of testicular germ cell tumors have evaluated various supportive and primary treatments. Bleomycin sulfate was evaluated in a Phase 3 trial where progression-free survival rates after one course were reported as 48% and 59% (p=0.05) 1. However, this treatment did not show a statistically significant improvement in overall survival (65% vs 73%, p=0.34) 1.

Filgrastim has been studied across multiple Phase 2 trials for use in patients with testicular germ cell tumors [3, 4, 5].

Recent results — preliminary, needs further review

  • Pegfilgrastim showed a 72% progression-free survival rate in a Phase 2 study 2.
  • Sunitinib malate was evaluated in a Phase 2 trial (N=10) 6.
  • Aprepitant was investigated for the control of acute vomiting, with 20% of participants achieving controlled vomiting (p=0.10) and 2 patients experiencing Grade 3, 4, or 5 toxicity 7.

For the clinician treating this condition

  • Bleomycin sulfate shows a statistically significant impact on progression-free survival after one course but does not significantly improve overall survival in the studied population 1.
  • Filgrastim has been investigated across multiple trials for this condition [3, 4, 5].

AI synthesis of 4 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Risk-stratified management framework proposed for testicular microlithiasis in infertile men
Diabetes & Endocrinology Cohort
Risk-stratified management framework proposed for testicular microlithiasis in infertile men Small Stones, Big Risks: New Guide for Testicular Health
This scoping review evaluated a risk-stratified management framework for testicular microlithiasis in infertile men compared to routine imag…
Men with small testicular stones need personalized care, not routine scans, unless they also have infertility or a family history of cancer.
Frontiers Apr 16, 2026

Research across Cancer

Related studies from across the Cancer family.

Radiomics features on MRI discriminate sellar LCH from tumor marker-negative GCTs with an AUC of 0.81
Pediatrics Cohort
Radiomics features on MRI discriminate sellar LCH from tumor marker-negative GCTs with an AUC of 0.81 AI Scan Helps Doctors Spot Confusing Brain Tumors
This retrospective cohort study evaluated 93 patients with sellar region tumors to discriminate between Langerhans cell histiocytosis (LCH) …
A new computer system helps doctors tell two similar brain tumors apart using MRI scans.
Frontiers Apr 24, 2026
Review highlights diagnostic challenges in testicular mucinous cystic neoplasm management
Oncology Sys. Review
Review highlights diagnostic challenges in testicular mucinous cystic neoplasm management A rare testicular cyst in an older man turned out to be a sign of hidden abdominal cancer
This case report and literature review describes a 78-year-old man who underwent scrotal exploration and right radical orchiectomy for a tes…
A rare testicular cyst in an older man turned out to be a sign of hidden abdominal cancer, highlighting the need for careful follow-up.
Frontiers Apr 22, 2026
Meta-analysis identifies germline susceptibility loci for rare cancers including MDS and GIST
Genetics & Precision Medicine Cohort
Meta-analysis identifies germline susceptibility loci for rare cancers including MDS and GIST Genes linked to rare cancers found in large study of over 480,000 people
This meta-analysis of observational cohorts from over 480,000 individuals identified novel germline susceptibility loci for rare cancers.
A huge study of over 480,000 people found new genes that raise the risk of several rare cancers, offering clues for families and doctors.
medRxiv Apr 22, 2026